GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » EBIT

Q32 Bio (Q32 Bio) EBIT : $-40.65 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio EBIT?

Q32 Bio's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-14.84 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-40.65 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Q32 Bio's annualized ROC % for the quarter that ended in Mar. 2024 was -231.99%. Q32 Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -746.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Q32 Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -20.81%.

Q32 Bio EBIT Historical Data

The historical data trend for Q32 Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio EBIT Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
EBIT
-36.69 -39.23 -48.26

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial -7.91 -7.37 - -25.81 -14.84

Competitive Comparison of Q32 Bio's EBIT

For the Biotechnology subindustry, Q32 Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Q32 Bio's EV-to-EBIT falls into.


Q32 Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio  (NAS:QTTB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Q32 Bio's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-59.372 * ( 1 - 0% )/( (22.76 + 28.425)/ 2 )
=-59.372/25.5925
=-231.99 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=47.057 - 9.69 - ( 25.617 - max(0, 14.109 - 28.716+25.617))
=22.76

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=152.334 - 18.819 - ( 135.312 - max(0, 32.953 - 138.043+135.312))
=28.425

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Q32 Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-59.372/( ( (8.083 + max(-10.349, 0)) + (7.819 + max(-26.137, 0)) )/ 2 )
=-59.372/( ( 8.083 + 7.819 )/ 2 )
=-59.372/7.951
=-746.72 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.344) - (9.69 + 0 + 3.003)
=-10.349

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.168) - (18.819 + 0 + 9.486)
=-26.137

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Q32 Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-40.652/195.330
=-20.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio EBIT Related Terms

Thank you for viewing the detailed overview of Q32 Bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Website
https://www.q32bio.com
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024